Cargando…

Clinical Benefit of Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Achieving Undetectable Minimal Residual Disease after Induction Treatment

Attaining undetectable minimal residual disease (MRD) is the current therapeutic goal for multiple myeloma. But there is a current lack of data regarding the clinical benefit of autologous stem cell transplantation (ASCT) for patients with myeloma achieving early MRD-negative status after induction...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Jiahui, Yan, Wenqiang, Fan, Huishou, Xu, Jingyu, Li, Lingna, Du, Chenxing, Mao, Xuehan, Yan, Yuting, Xu, Yan, Sui, Weiwei, Deng, Shuhui, Yi, Shuhua, Anderson, Kenneth C., Qiu, Lugui, Zou, Dehui, An, Gang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Association for Cancer Research 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10481879/ https://www.ncbi.nlm.nih.gov/pubmed/37680953 http://dx.doi.org/10.1158/2767-9764.CRC-23-0185

Ejemplares similares

Impact of residual tumor cells in the stem cell collection on multiple myeloma patients receiving autologous stem cell transplantation
por: Xu, Jingyu, et al.
Publicado: (2023)

Prognostic value of the Second Revision of the International Staging System (R2-ISS) in a real-world cohort of patients with newly-diagnosed multiple myeloma
por: Yan, Wenqiang, et al.
Publicado: (2023)

P910: DOES MINIMAL RESIDUAL DISEASE OF STEM CELL COLLECTION HAVE PROGNOSTIC IMPACT ON PATIENTS WITH MULTIPLE MYELOMA?
por: Jingyu, X., et al.
Publicado: (2022)

PB2005: BORTEZOMIB, LENALIDOMIDE AND DEXAMETHASONE IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS: A REAL-WORLD STUDY OF CHINA
por: Jingyu, X., et al.
Publicado: (2022)

P935: EARLY RELAPSE WITHIN 18 MONTHS (ER18) IS A POWERFUL DYNAMIC PREDICTOR FOR PROGNOSIS AND COULD REVISE STATIC RISK DISTRIBUTION IN PATIENTS WITH NEWLY-DIAGNOSED MULTIPLE MYELOMA
por: Yan, Wenqiang, et al.
Publicado: (2023)

Clonal phylogeny and evolution of critical cytogenetic aberrations in multiple myeloma at single-cell level by QM-FISH
por: Yan, Yuting, et al.
Publicado: (2022)

MicroRNA-15a/16-1 cluster located at chromosome 13q14 is down-regulated but displays different expression pattern and prognostic significance in multiple myeloma
por: Li, Fei, et al.
Publicado: (2015)

P844: GLOBAL CHARACTERIZATION OF MONOCYTE REVEALS A STRESS SIGNATURE INDUCED BY MULTIPLE MYELOMA BY SINGLE-CELL RNA SEQUENCING
por: Cui, Jian, et al.
Publicado: (2023)

Serum high expression of miR-214 and miR-135b as novel predictor for myeloma bone disease development and prognosis
por: Hao, Mu, et al.
Publicado: (2016)

Suppressing miRNA-15a/-16 expression by interleukin-6 enhances drug-resistance in myeloma cells
por: Hao, Mu, et al.
Publicado: (2011)

Detection of recurrent cytogenetic aberrations in multiple myeloma: A comparison between MLPA and iFISH
por: Zang, Meirong, et al.
Publicado: (2015)

Aberrant metabolic processes promote the immunosuppressive microenvironment in multiple myeloma
por: Lv, Junqiang, et al.
Publicado: (2022)

Multiple myeloma hinders erythropoiesis and causes anaemia owing to high levels of CCL3 in the bone marrow microenvironment
por: Liu, Lanting, et al.
Publicado: (2020)

P806: TRACKING THE CLONAL EVOLUTION AND DRUG RESISTANCE PATHWAY OF NEWLY DIAGNOSED MULTIPLE MYELOMA THROUGH SINGLE-CELL RNA SEQUENCING
por: Cui, Jian, et al.
Publicado: (2023)

Immunotherapy for multiple myeloma: new chances and hope
por: Xu, Jingyu, et al.
Publicado: (2023)

Heterogeneous chromosome 12p deletion is an independent adverse prognostic factor and resistant to bortezomib-based therapy in multiple myeloma
por: Li, Fei, et al.
Publicado: (2015)

Real-world treatment patterns, discontinuation and clinical outcomes in patients with B-cell lymphoproliferative diseases treated with BTK inhibitors in China
por: Yan, Yuting, et al.
Publicado: (2023)

P1162: FRONT-LINE RISK-ADAPTED THERAPY PRESENTED FAVORABLE OUTCOMES FOR YOUNG PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA: RESULTS FROM A CONSECUTIVE COHORT IN CHINA
por: Zou, Hesong, et al.
Publicado: (2023)

Current treatment paradigm and survival outcomes among patients with newly diagnosed multiple myeloma in China: a retrospective multicenter study
por: Fan, Huishou, et al.
Publicado: (2023)

Minimal residual disease status improved the response evaluation in patients with Waldenström’s macroglobulinemia
por: Xiong, Wenjie, et al.
Publicado: (2023)

Cdc37 suppression induces plasma cell immaturation and bortezomib resistance in multiple myeloma via Xbp1s
por: Zang, Meirong, et al.
Publicado: (2020)

Distinct clinical characteristics draw a new prognostic model for splenic marginal zone lymphoma in HBV high prevalent region
por: Yi, Shuhua, et al.
Publicado: (2017)

Single-cell profiles reveal tumor cell heterogeneity and immunosuppressive microenvironment in Waldenström macroglobulinemia
por: Sun, Hao, et al.
Publicado: (2022)

Elevated neutrophil-to-lymphocyte ratio and monocyte-to-lymphocyte ratio and decreased platelet-to-lymphocyte ratio are associated with poor prognosis in multiple myeloma
por: Shi, Lihui, et al.
Publicado: (2016)

Del17p does not always significantly influence the survival of B-cell chronic lymphoproliferative disorders
por: Yi, Shuhua, et al.
Publicado: (2017)

Benefit of rituximab maintenance is associated with Follicular Lymphoma International Prognostic Index in patients with follicular lymphoma
por: Li, Ru, et al.
Publicado: (2022)

Exosome miRNAs profiling in serum and prognostic evaluation in patients with multiple myeloma
por: Fang, Teng, et al.
Publicado: (2023)

Multiple myeloma–derived miR‐27b‐3p facilitates tumour progression via promoting tumour cell proliferation and immunosuppressive microenvironment
por: Wei, Xiaojing, et al.
Publicado: (2023)

Superior efficacy of rituximab-based chemoimmunotherapy as an initial therapy in newly diagnosed patients with B cell indolent lymphomas: long-term results from a single center in China
por: Li, Zengjun, et al.
Publicado: (2015)

Targeting stem cell niche can protect hematopoietic stem cells from chemotherapy and G-CSF treatment
por: Li, Sidan, et al.
Publicado: (2015)

Cytogenetic aberrations of lymphoplasmacytic lymphoma/Waldenström's macroglobulinemia in Chinese patients
por: Xiong, Wenjie, et al.
Publicado: (2023)

The association of HLA-C alleles with multiple myeloma in Chinese patients
por: Wang, Xiaojing, et al.
Publicado: (2018)

BCL-2 and MYC gain/amplification is correlated with central nervous system involvement in diffuse large B cell lymphoma at leukemic phase
por: Zou, Dehui, et al.
Publicado: (2017)

Contrast-enhanced ultrasound manifestations of renal masses undetectable on conventional ultrasound
por: Tao, Lingling, et al.
Publicado: (2022)

Four and a Half LIM Domains Protein 2 Mediates Bortezomib-Induced Osteogenic Differentiation of Mesenchymal Stem Cells in Multiple Myeloma Through p53 Signaling and β-Catenin Nuclear Enrichment
por: Xie, Zhenqing, et al.
Publicado: (2021)

Uncovering undetected hypoglycemic events
por: Unger, Jeff
Publicado: (2012)

Classical Imaging with Undetected Photons
por: Shapiro, Jeffrey H., et al.
Publicado: (2015)

The benefits of treating undetectable tumors
por: Komarova, Natalia L
Publicado: (2015)

Estimating undetected Ebola spillovers
por: Glennon, Emma E., et al.
Publicado: (2019)

Quantum holography with undetected light
por: Töpfer, Sebastian, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_e1ltjon175htrjdfqlmit67sth